Arvinas to report Q1 2026 financial results on May 12 with a live webcast update.

Arvinas, a biotech company specializing in targeted protein degradation therapies, will announce its first quarter 2026 financial results on May 12, 2026. The company will provide a corporate update via a live webcast accessible on its investor website. Arvinas recently gained FDA approval for VEPPANU, the first PROTAC drug for advanced breast cancer, and is advancing several other drug candidates in clinical trials. This update will offer insights into their financial health and progress in drug development.